The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 357-361 , April 2008

Decay-accelerating Factor Expression May Provide Immunoprotection Against Antibody-mediated Cardiac Allograft Rejection

Presented at the poster session of the 2006 World Transplant Congress, Boston, Massachusetts, July 2006.

Received 3 August 2007 ,Revised 6 November 2007 ,Accepted 2 January 2008.

References 

  1. Hammond EH, Yowell RL, Price GD, et al. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant. 1992;11(suppl):S111–S119
  2. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58–69
  3. Kaczmarek I, Deutsch MA, Sadoni S, et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant. 2007;26:511–515
  4. Lones MA, Czer LS, Trento A, et al. Clinical–pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant. 1995;14:151–162
  5. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4:1033–1041
  6. Byrne GW, McCurry KR, Martin MJ, et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation. 1997;63:149–155
  7. Frank M, Reid K, Galli S, Rajewsky K. The humoral immune response. In: 4th ed.. London: Elsevier; 1999;p. 635
  8. Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant. 2005;5:2778–2785
  9. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25:153–159
  10. Mason JC, Lidington EA, Yarwood H, Lublin DM, Haskard DO. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum. 2001;44:138–150
  11. Mason JC, Yarwood H, Sugars K, et al. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood. 1999;94:1673–1682
  12. Adams DH, Kadner A, Chen RH, Farivar RS. Human membrane cofactor protein (MCP, CD46) protects transgenic pig hearts from hyperacute rejection in primates. Xenotransplantation. 2001;8:36–40
  13. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med. 1995;1:423–427
  14. Scoazec JY, Delautier D, Moreau A, et al. Expression of complement-regulatory proteins in normal and UW-preserved human liver. Gastroenterology. 1994;107:505–516
  15. Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol. 2004;172:3869–3875
  16. Davitz MA, Low MG, Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC) (Selective modification of a complement regulatory protein). J Exp Med. 1986;163:1150–1161
  17. Kawada M, Mizuno M, Nasu J, et al. Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. J Lab Clin Med. 2003;142:306–312
  18. Metz CN, Brunner G, Choi-Muira NH, et al. Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J. 1994;13:1741–1751
  19. Sharom FJ, Lehto MT. Glycosylphosphatidylinositol-anchored proteins: structure, function, and cleavage by phosphatidylinositol-specific phospholipase C. Biochem Cell Biol. 2002;80:535–549
  20. Nasu J, Mizuno M, Uesu T, et al. Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol. 1998;113:379–385
  21. Tausk F, Fey M, Gigli I. Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells. J Immunol. 1989;143:3295–3302
  22. Ahmad SR, Lidington EA, Ohta R, et al. Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition. Immunology. 2003;110:258–268
  23. Liu J, Miwa T, Hilliard B, et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med. 2005;201:567–577

PII: S1053-2498(08)00009-0

doi: 10.1016/j.healun.2008.01.008

The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 357-361 , April 2008

Article Tools

* Image Usage & Resolution